GSK 2879552

Drug Profile

GSK 2879552

Alternative Names: GSK-2879552

Latest Information Update: 13 Oct 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antineoplastics
  • Mechanism of Action Co-repressor protein inhibitors; Lysine specific demethylase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Small cell lung cancer
  • Preclinical Myelodysplastic syndromes

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 07 Oct 2016 GlaxoSmithKline plans a phase I/II trial for Myelodysplastic syndromes (Monotherapy, Combination therapy, Second-line therapy or greater) in USA, Canada and Europe (PO) (NCT02929498)
  • 27 Sep 2016 Preclinical trials in Myelodysplastic syndromes in United Kingdom (PO) before September 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top